Finanzen von Atrium Therapeutics Inc (RNA)RNAAtrium Therapeutics Inc

Evaluating the bottom line, Atrium Therapeutics Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -752.93%, while the net margin is -671.97%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively RNA converts its operational activities into shareholder value.

In the context of the broader market, RNA competes directly with industry leaders such as WHWK and ZNTL. With a market capitalization of $142.36M, it holds a significant position in the sector. When comparing efficiency, RNA's gross margin of 100.00% stands against WHWK's N/A and ZNTL's N/A. Such benchmarking helps identify whether Atrium Therapeutics Inc is trading at a premium or discount relative to its financial performance.

The company has shown a gross margin of 100% in recent quarters, indicating strong revenue generation relative to costs, despite net losses. The current ratio has improved to 13.04 in Q1 2026, suggesting better liquidity.